NCT01571388已完成1 期
A Phase 1 Study To Evaluate The Single Dose Pharmacokinetics Of Dacomitinib (PF-00299804) In Subjects With Impaired Hepatic Function
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Maximum Observed Plasma Concentration (Cmax)
研究概览
简要总结
The study will determine if there are differences in how dacomitinib is absorbed and eliminated between healthy subjects and subjects with mild and moderately impaired hepatic function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and/or female subjects of non-childbearing potential between the ages of 18 years of age to <75 years of age. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests. Liver function tests, albumin and prothrombin time must be within normal range.
- •Body Mass Index (BMI) of 18 to 35 kg/m2;
- •An informed consent document signed and dated by the subject.
- •Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •Subjects in the normal hepatic function group (Group 1): No known or suspected hepatic impairment.
- •For subjects in the hepatic impairment groups (Groups 2 and 3):
- •Should satisfy the criteria for Class A or B of the modified Child-Pugh classification
- •A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination, liver biopsy, hepatic ultrasound, CT scan, or MRI.
- •Stable hepatic impairment, defined as no clinically significant change in disease status within the last 30 days, as documented by the subject's recent medical history
- •Must be on a stable dose of medication and/or treatment regimen.
排除标准
- •Any condition possibly affecting drug absorption (eg, gastrectomy, chronic diarrhea, rapid transit).
- •A positive urine drug screen.
- •Females of childbearing potential, including those with tubal ligation. [To be considered for enrollment, women of at least 45 years of age who are postmenopausal (defined as being amenorrheic for at least 2 years) must have confirmatory FSH test results at screening].
- •In addition, subjects in the hepatic impairment groups (Groups 2 and 3) presenting with any of the following will not be included in the trial:
- •Hepatic carcinoma and hepatorenal syndrome or life expectancy <1 year.
- •Undergone porta-caval shunt surgery.
- •History of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less than one month prior to study entry.
研究组 & 干预措施
Group 1
Experimental
Healthy Subjects to receive dacomitinib
干预措施: dacomitinib (Drug)
Group 2
Experimental
Subjects with mildly impaired hepatic function to receive dacomitinib
干预措施: dacomitinib (Drug)
Group 3
Experimental
Subjects with moderately impaired hepatic function to receive dacomitinib
干预措施: dacomitinib (Drug)
结局指标
主要结局
Maximum Observed Plasma Concentration (Cmax)
时间窗: 2 weeks
Maximal plasma concentration (Cmax) for dacomitinib
Plasma area under plasma concentration-time curve from time zero to time infinity post dose (AUCinf) for dacomitinib
时间窗: 2 weeks
次要结局
- Time of first observed maximal plasma concentration (Tmax) for dacomitinib(2 weeks)
- Plasma elimination half life (t1/2) of dacomitinib(2 weeks)
- Apparent plasma clearance (CL/F) of dacomitinib(2 weeks)
- Apparent volume of distribution (Vz/F) of dacomitinib(2 weeks)
- Fraction of unbound dacomitinib in plasma (fu)(2 weeks)
- Unbound apparent plasma clearance (CL/F) of dacomitinib ,(2 weeks)
- Unbound apparent volume of distribution (Vz/F) of dacomitinib(2 weeks)
- Metabolite ratio for plasma area under plasma concentration-time curve from time zero to time infinity post dose (MRAUCinf)(2 weeks)
- Plasma area under plasma concentration-time curve from time zero to time of last quantifiable concentration post dose (AUClast) for PF-05199265(2 weeks)
- Area under the Concentration-Time Curve (AUC);Plasma area under plasma concentration-time curve from time zero to 24 hours post dose (AUC24) for dacomitinib(2 weeks)
- Plasma area under plasma concentration-time curve from time zero to 216 hours post dose (AUC216) for dacomitinib(2 weeks)
- Plasma area under plasma concentration-time curve from time zero to time of last quantifiable concentration post dose (AUClast) for dacomitinib(2 weeks)
- Maximal plasma concentration (Cmax) for PF-05199265(2 weeks)
- Time of first observed maximal plasma concentration (Tmax) for PF-05199265(2 weeks)
- Metabolite ratio for plasma area under plasma concentration-time curve from time zero to time of last quantifiable concentration post dose (MRAUClast)(2 weeks)
- Metabolite ratio for maximal plasma concentration (MRCmax)(2 weeks)
- Fraction of unbound PF-05199265 in plasma (fu)(2 weeks)
- Unbound plasma area under plasma concentration-time curve from time zero to 24 hours post dose (AUC24) for PF-05199265(2 weeks)
- Unbound plasma area under plasma concentration-time curve from time zero to 216 hours post dose (AUC216) for PF-05199265(2 weeks)
- Unbound plasma area under plasma concentration-time curve from time zero to time of last quantifiable concentration post dose (AUClast) for PF-05199265(2 weeks)
- Unbound Plasma area under plasma concentration-time curve from time zero to time infinity post dose (AUCinf) for PF-05199265(2 weeks)
- Maximal unbound plasma concentration (Cmax) for PF-05199265(2 weeks)
- Overall safety profile as characterized by laboratory abnormalities, observed physical examination, vital signs, ECGs, and adverse event monitoring.(6-8 weeks)
- Unbound Plasma area under plasma concentration-time curve from time zero to time infinity post dose (AUCinf) for dacomitinib(2 weeks)
- Unbound plasma area under plasma concentration-time curve from time zero to 24 hours post dose (AUC24) for dacomitinib(2 weeks)
- Unbound plasma area under plasma concentration-time curve from time zero to 216 hours post dose (AUC216) for dacomitinib(2 weeks)
- Unbound plasma area under plasma concentration-time curve from time zero to time of last quantifiable concentration post dose (AUClast) for dacomitinib(2 weeks)
- Maximal unbound plasma concentration (Cmax) for dacomitinib(2 weeks)
- Plasma area under plasma concentration-time curve from time zero to time infinity post dose (AUCinf) for PF-05199265(2 weeks)
- Plasma area under plasma concentration-time curve from time zero to 24 hours post dose (AUC24) for PF-05199265(2 weeks)
- Plasma area under plasma concentration-time curve from time zero to 216 hours post dose (AUC216) for PF-05199265(2 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of Mirikizumab (LY3074828) Injection in Healthy ParticipantsHealthyNCT03053622Eli Lilly and Company67
已完成
1 期
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics of DWP16001 Drug A and CHealthy VolunteersNCT05465668Daewoong Pharmaceutical Co. LTD.43
已完成
1 期
Single Oral Dose Escalation Study of DNDI-0690 in Healthy SubjectsVisceral LeishmaniasisCutaneous LeishmaniasesNCT03929016Drugs for Neglected Diseases64
已完成
1 期
Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)Renal InsufficiencyNCT01512667Merck Sharp & Dohme LLC25
已完成
1 期
Oral Remimazolam With and Without Alcohol in Healthy Female SubjectsSafety IssuesNCT04113343Paion UK Ltd.21